Journey Medical Corp (DERM) Stock Price, Quote & News

Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 480 434 6670

Website: journeymedicalcorp.com

Address:

9237 East Via de Ventura Boulevard, Suite 105, Scottsdale, United States

omega42 Jan. 14 at 2:35 AM

$DERM projection for Q4 and FY2026 based on the current scrip growth and per scrip revenue. Heavy use of coupons to promote Emrosi heavily impacts revenue but great way to promote. Once couponing slows down average price will increase at which point revenue will become signifcant. add to other current revenue and next year they could hit $100M with 4 multiple thats SP of $16 at minimum.

0 · Reply

IBUYSELLHOLD Jan. 13 at 6:55 PM

$DERM /swing some into fbio

2 · Reply

IBUYSELLHOLD Jan. 13 at 6:52 PM

$DERM /great day for a swing !!

0 · Reply

buymoremakemore Jan. 13 at 6:31 PM

$DERM Now that FBIO has more opportunities to generate revenue with the cyperium approval, even if not a lot, we could see more SP support here at DERM since FBIO owns 37% of float.

1 · Reply

Tomasini Jan. 13 at 5:04 PM

$DERM holding gains. notnormal

0 · Reply

PatrickandFrankie Jan. 13 at 12:28 PM

$DERM $FBIO seriously??? So according to this post if management delivers good news and wall street plays games with the stock price that compromises trust in the management of both of these companies???

1 · Reply

omega42 Jan. 13 at 2:07 AM

$FBIO $FBIOP $DERM million $ questions is whether PRV will be given. suprisingly quiet from the company and its unusually for FDA news to be released before the company's PR. typically 24hrs after delivering the FDA communication to the company. If no PRV, this will tank tomorrow as the product revenues stay with Sentynl and only royalties which will be very small. with Derm being at $7 and $200M MC, it is no brainer as deeply undervalued

3 · Reply

omega42 Jan. 5 at 6:51 PM

$DERM hello $7 again. good day to add some. Scripts are growing and not sure if anyone noticed, that growth has been supported by greater internal promotional spend to get patients to try and change to emrosi. Great marketing strategy. With that being said, expecting strong Q4 script growth, and starting with Q2/Q3 awareness should be there at which point we'll get to see higher per script revenue. This is at $200M MC, while expecting it to double if not triple in the near future.

0 · Reply

FinSUN Jan. 5 at 6:41 PM

$DERM bye biotechs. A few chips for the pudfa. see ya later

1 · Reply

garygb Jan. 5 at 6:32 PM

$DERM bottom buy

0 · Reply

Market Cap	210.03M
Revenue (ttm)	56.13M
Net Income (ttm)	-14.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	26.93
Profit Margin	-26.14%
Debt to Equity Ratio	0.97

Volume	120,100
Avg Vol	171,918
Day's Range	N/A - N/A
Shares Out	27.14M
Stochastic %K	90%
Beta	0.81
Analysts	Strong Sell
Price Target	$13.50